# Diabetes Research Hub — Monitor Report

**Date:** 2026-05-23
**Scan time:** 07:05 (hub_monitor.py) + scheduled review run
**Previous monitor report:** monitor_report_2026-05-22.md
**Comparison snapshots:** clinical_trials_snapshot_2026-05-22 → 2026-05-23 (1 day); pubmed_recent_snapshot_2026-05-22 → 2026-05-23 (1 day)

---

## File System Status

All four daily pipeline outputs ran on schedule. Hub now tracks **853 files** (+5 new, 28 modified since yesterday).

| File | Last modified | Status |
|------|---------------|--------|
| hub_monitor_report.md | 2026-05-23 07:05 | Fresh |
| clinical_trials_latest.json | 2026-05-23 07:04 | Fresh (797 trials, +2 vs yesterday) |
| pubmed_recent_latest.json | 2026-05-23 07:05 | Fresh (150 papers, 30-day window) |
| clinical_trials_summary.md | 2026-05-23 07:04 | Fresh |
| pubmed_recent_summary.md | 2026-05-23 07:05 | Fresh |
| literature_gap_report.md | 2026-05-22 08:07 | Fresh (regenerated yesterday) |
| literature_gap_data.json | 2026-04-20 15:35 | **STALE — 33 days old** |
| literature_gap_matrix.xlsx | 2026-04-20 15:35 | **STALE — 33 days old** |
| agent_state.json | 2026-05-22 08:08 | Fresh |
| citation_validation.json | 2026-05-22 08:07 | Fresh |

Note: hub_monitor flags 596 result files older than 14 days; the vast majority are dated snapshot files (`clinical_trials_snapshot_*`, `pubmed_recent_snapshot_*`) intentionally retained for trend analysis — not actionable staleness.

**True staleness flag:** the underlying gap-analysis numerical data (`literature_gap_data.json`, `literature_gap_matrix.xlsx`) has not been regenerated since 2026-04-20. The human-readable `literature_gap_report.md` was rewritten yesterday but is still based on April 20 data.

---

## Clinical Trial Changes

### Snapshot diff (2026-05-22 → 2026-05-23)
Per `hub_monitor_report.md` and direct comparison:

- **New trials: 3**
  - `NCT07604922` (NA, NOT_YET_RECRUITING) — Vascular properties of HEMI and SPG signals in individuals at risk for diabetes — INSERM (France)
  - `NCT07602036` (NA, NOT_YET_RECRUITING) — T2D and Pregnancy single-arm interventional — Poznan Univ. Medical Sciences
  - `NCT03919877` (NA, COMPLETED) — Precision Diets for Diabetes Prevention — Stanford. Newly indexed into our hub via the "Recently Completed with Results" feed; results were posted 2026-05-22 (see below).
- **Removed: 1**
  - `NCT06672172` (Phase 3, ACTIVE_NOT_RECRUITING) — HRS-7535 vs Placebo in T2D + Inadequate Glycemic Control. Likely re-categorized or completion-aged out of the active feed.
- **Status changes: 1**
  - `NCT07372872` `NOT_YET_RECRUITING → RECRUITING` — Feasibility testing of the "MyGlucoCare" app for women with gestational diabetes.
- **New results posted today: 1**
  - `NCT03919877` (results_posted 2026-05-22) — Stanford "Precision Diets for Diabetes Prevention." Worth a look given the cross-domain match with our personalized-nutrition gap area (see Gap Analysis below).

### Key Phase 3 watchlist — current status (sponsor-screened)

No change in any tracked Phase 3 trial today. Carrying forward from yesterday:

| Trial | Drug/Therapy | Sponsor | Phase | Status |
|-------|--------------|---------|-------|--------|
| NCT06832410 | VX-880 (zimislecel) | Vertex | 3 | RECRUITING |
| NCT04786262 | VX-880 (long-running) | Vertex | 3 | RECRUITING |
| NCT07222137 | Baricitinib — delay stage 3 T1D | Eli Lilly | 3 | RECRUITING |
| NCT07222332 | Baricitinib — preserve β-cell in children | Eli Lilly | 3 | RECRUITING |
| NCT07076199 | Insulin icodec | Novo Nordisk | 3 | RECRUITING |
| NCT07088068 | Teplizumab vs placebo (newly recruiting tracking) | Sanofi | 3 | RECRUITING |
| NCT06914895 | Tirzepatide in T1D | Eli Lilly | 3 | ACTIVE_NOT_RECRUITING |
| NCT06962280 | Long-term tirzepatide in T1D | Eli Lilly | 3 | ACTIVE_NOT_RECRUITING |
| NCT05929079 | Retatrutide in T2D | Eli Lilly | 3 | ACTIVE_NOT_RECRUITING |
| NCT06993792 | Orforglipron in obesity + T2D | Eli Lilly | 3 | ACTIVE_NOT_RECRUITING |
| NCT06534411 | CagriSema, T2D | Novo Nordisk | 3 | ACTIVE_NOT_RECRUITING |

**Total Phase 3 RECRUITING trials in the hub:** 46. **Total trials with posted results:** 282 (+1 today).

**Sana Biotechnology check:** still 0 trials in the hub feed — confirm whether their hypoimmune islet program (UP421 / pancreatic islet cells) is enrolled under a partner sponsor name rather than "Sana" before concluding it is absent.

---

## PubMed Highlights

### Volume
150 unique papers in the 30-day window across 16 alert domains (+2 vs yesterday's 148). Day-over-day: **27 new papers, 25 dropped** as the rolling window shifted forward.

### Cross-Domain Papers (highest priority — papers tagged in 2+ alert domains)

12 cross-domain papers in the current window. Six are **new today** (matching hub_monitor's auto-flagged list):

| PMID | Date | Title (truncated) | Domains | Journal |
|------|------|-------------------|---------|---------|
| 42169233 | 2026-May-21 | Hyperbaric oxygen in the AI era: integration and innovation | Diabetes AI/ML × Multi-Omics | Medical Gas Research |
| 42169644 | 2026-Jul | Diagnostic markers for diabetic kidney disease via WGCNA + ML | Diabetes AI/ML × Biomarker | Int J Mol Med |
| 42171301 | 2026-May-21 | Dietary diversity & T2D in two Chinese cohorts: multi-omics | Biomarker × Microbiome × Multi-Omics | Food & Function |
| 42171425 | 2026-May-01 | HDGF as serological marker for proliferative DR: Mendelian randomization | Biomarker × Complications New | Transl Vis Sci Tech |
| 42171711 | 2026-May-22 | Epigenetic signatures in T2D: therapeutic advances + lifestyle | T2D Remission × Epigenetics | Acta Diabetologica |
| 42171725 | 2026-May-22 | Synthetic data-driven DR diagnosis with explainable AI | AI/ML × Complications New | Graefe's Archive |

Existing cross-domain papers still in window:

- `[42163482]` Extracellular vesicle proteins as T1D biomarkers — T1D Stem Cell × T1D Immunotherapy (Proteomics)
- `[42148104]` Adapting CAR-T / CAR-Treg cancer therapies for autoimmunity — T1D Stem Cell × T1D Immunotherapy
- `[42143506]` CAR therapies across oncology + autoimmunity — T1D Immunotherapy × Gene Therapy
- `[42167398]` Multi-omics atlas of multisystem complications in T2D — AI/ML × Multi-Omics (Metabolism)
- `[42167392]` Precise DR staging via ML analysis of leakage sources — Biomarker × Complications New
- `[42163256]` Tissue-specific effects of glucose-lowering drugs on aging via DNA methylation — Epigenetics × Multi-Omics (BMC Medicine)

The dietary-diversity multi-omics paper (`42171301`, three domains) and the BMC Medicine epigenetics-of-glucose-lowering-drugs paper (`42163256`) are the two highest-density signals worth a read.

### Key Therapy Mentions (last 30 days)

| Therapy | Papers in window | Notable items |
|---------|------------------|---------------|
| dapagliflozin | 5 indexed (38 raw hits) | 5 new today: LA volume reduction in T2D (`42171707`); glucosamine→mTORC1 glucose toxicity (`42171606`); microvascular hemorheology RCT (`42170890`); CircUBE3A in diabetic endothelium (`42167451`); dapa+spironolactone vs mono for albuminuria/hyperkalemia (`42167409`) |
| teplizumab | 5 (6 raw) | EV protein biomarker paper (`42163482`); islet autoantibody ordering post-approval (`42138126`); new/emerging T1D therapies review (`42138080`); BSPED consensus for stage 2 use (`42051156`); 3-adult feasibility series (`41796109`) |
| icodec | 5 | Simplified switching protocol without loading dose (`42168822` — new today); ONWARDS 1-6 pooled safety (`42119975`); efsitora-alfa comparison review (`42048049`); China cost-utility (`41705603`); Chinese-language clinical-value review (`42161872`) |
| retatrutide | 5 | Dysesthesia signal in GLP-1 data-mining (`42168638`); retrospective bariatric audit (`42142983`); lipid/metabolite profiles in obesity ± T2D (`42135195`); triple-agonist + CKM syndrome review (`42108533`); BP effects meta-analysis (`40899050`) |
| orforglipron | 3 | ATTAIN-MAINTAIN Phase 3b (`42120723`); GI safety network meta-analysis (`42116665`); CVOT Summit Report 2025 (`42092956`) |
| CagriSema | 2 | vs semaglutide monotherapy systematic review/MA (`41759565`); bariatric audit (`42142983`) |
| baricitinib | 2 | Hashimoto resolution case (`42039112`); generalized actinic granuloma case (`41761435`) — neither in T1D context, despite our Phase 3 watch on baricitinib for β-cell preservation |
| **zimislecel** | **0** | **No PubMed indexing of VX-880's INN this window — first peer-reviewed paper using "zimislecel" remains absent.** Worth noting as a literature gap given two Phase 3 trials are recruiting. |

### Domain volume snapshot
12 of 16 alert domains are at the 10-paper cap (esearch retmax). Below-cap domains: Epigenetics (9), Drug Repurpose (6), LADA (6), GLP-1 Pharmacogenomics (1). The GLP-1 pharmacogenomics floor matches yesterday and continues to suggest a real publication scarcity, not a query bug.

---

## Gap Analysis Summary

Source: `literature_gap_report.md` (regenerated 2026-05-22 from 2026-04-20 underlying data — see staleness flag).

**Top 5 highest-gap intersections (all Gap Score = 100.0):**

1. **Beta Cell Regen × Health Equity** — 0 joint pubs. Who gets cell therapy?
2. **Insulin Resistance × Islet Transplant** — 1 joint pub. Graft survival in IR recipients.
3. **Islet Transplant × Drug Repurposing** — 0 joint pubs. Computational screen for immunoprotective repurposing.
4. **Islet Transplant × Health Equity** — 0 joint pubs. Access to transplant centers.
5. **Gene Therapy × LADA** — 0 joint pubs. Autoimmune-mechanism gene therapy in LADA.

**Alignment with our contribution areas (CONTRIBUTION_STRATEGY.md):**

- Ranks 1, 3, 4 all touch **Islet Transplant** — directly relevant to our cell-therapy / repurposing work (cf. `islet_repurposing_*` outputs from April 3).
- Rank 5 (Gene Therapy × LADA) maps to our LADA dashboard area, which is currently dormant — could be a candidate for the next iterate cycle.
- Today's cross-domain Stanford trial (`NCT03919877`, Precision Diets for Diabetes Prevention) is interesting alongside several gap pairs involving **Personalized Nutrition** (rank 11, 15; multiple "Unclassified" rows).

---

## Breaking News (last 7 days)

Triple-checked against current ClinicalTrials.gov snapshot, no overlap missed.

- **2026-05-21 — Eli Lilly TRIUMPH-1 Phase 3 retatrutide results (OBESITY)**. All three doses (4, 9, 12 mg) met primary + key secondary endpoints. **No corresponding PubMed entry yet — press release stage.** Tracker NCT(s) in our hub for retatrutide remain ACTIVE_NOT_RECRUITING (NCT05929079 for T2D, plus separate obesity NCTs). PubMed PMID `42135195` (May 14) on retatrutide lipid/metabolite profiles is the closest indexed signal so far. Sources: [PR Newswire](https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-demonstrated-significant-reductions-in-a1c-and-weight-in-first-phase-3-trial-for-treatment-of-type-2-diabetes-302718589.html); [AJMC TRIUMPH-1 30.3% weight-loss summary](https://www.ajmc.com/view/retatrutide-achieves-up-to-30-3-average-weight-loss-in-phase-3-triumph-1-trial). Note headline-vs-trial-name discrepancy — "TRIUMPH-1" branding is now being used for the obesity readout; if our `retatrutide` tracker mapped TRIUMPH-1 to T2D, that mapping needs updating.
- **2026-05-29 (pending) — FDA PDUFA decision** on Afrezza pediatric expansion (inhaled insulin in children/adolescents with T1D or T2D). Would be the first needle-free pediatric insulin if approved. Source: [Cardiology Advisor — FDA May 2026 decisions](https://www.thecardiologyadvisor.com/news/fda-drug-approval-decisions-expected-in-may-2026/).
- **2026-04-29 — FDA approved Langlara (insulin glargine-aldy)**, interchangeable biosimilar to Lantus. Already past our 7-day window but flagged because it has not appeared in any of our trial snapshots; we may want to add insulin biosimilars as a hub topic. Source: [FDA Novel Drug Approvals 2026](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026).
- **2026-04-22 — Sanofi Tzield (teplizumab-mzwv) sBLA approved** to age 1+ for delay of stage 3 T1D. Relates directly to our active teplizumab tracking; our PubMed feed has multiple downstream papers (`42138126`, `42051156`, `41796109`, `42138080`). Source: [Sanofi press release](https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-22-05-05-00-3278650).

No other Phase 3 readouts or FDA actions in the last 7 days rose above the routine-news threshold.

---

## Recommended Actions

1. **Refresh stale gap data** — `literature_gap_data.json` and `literature_gap_matrix.xlsx` are 33 days old. Run: `python project1_literature_gap_analysis.py`. The narrative report is current but the numerical inputs have aged out of the Doctrine's 30-day Tier-1 freshness target.
2. **Update Diabetes_Research_Tracker.xlsx with TRIUMPH-1 retatrutide readout** — Phase 3 results are press-released but not yet on ClinicalTrials.gov's `has_results` flag for any of our tracked NCTs. Add a manual entry with evidence level B2 (press release, not peer-reviewed) and watch for the corresponding NCT update.
3. **Verify Sana Biotechnology hub coverage** — feed shows 0 trials. Re-check by searching ClinicalTrials.gov for "hypoimmune" / "UP421" / "pancreatic islet cells" without restricting to "Sana" sponsor field.
4. **Review today's cross-domain papers** (high priority):
   - PMID `42171301` — dietary diversity × T2D, three-domain (Biomarker, Microbiome, Multi-Omics)
   - PMID `42163256` — glucose-lowering drug effects on aging via DNA methylation, BMC Medicine, Epigenetics × Multi-Omics
   - PMID `42167398` — multi-omics atlas of T2D complications, Metabolism
5. **Review Stanford Precision Diets results** (NCT03919877, results posted 2026-05-22) — intersects with our currently dormant Personalized Nutrition gap area; could justify a follow-up extraction into the paper library if abstract holds up.
6. **Consider a baricitinib-T1D PubMed query** — only 2 baricitinib papers indexed in window, neither in T1D context, yet Eli Lilly has two Phase 3 baricitinib trials in T1D recruiting (NCT07222332, NCT07222137). Either our search string is too narrow or there is a real literature lag worth flagging.
7. **Add "zimislecel" tracking note** — the INN remains unindexed in PubMed despite two recruiting Phase 3 trials. Watch carefully; first peer-reviewed paper will be a milestone.

---

## Validation & Evidence Levels

Per Research Doctrine v1.0:

- File counts, snapshot diffs, PubMed metadata: **GOLD** — verifiable directly from JSON.
- Cross-domain paper tagging: **SILVER** — derived from our domain query strings; not exact MeSH.
- Gap-analysis interpretations: **BRONZE** — single analytical source, requires expert validation.
- Breaking news items: **B2 (press releases)** until peer-reviewed publication appears. Search results are listed in the inline sources above.

---

*Generated by scheduled diabetes-hub-monitor task — 2026-05-23. Review only; no source files modified.*
